---

$1.66

-0.0050 ( -0.30% ) 347.0K

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-10-23	Buy	365000.00	Munshi Amit
2024-10-23	Buy	145000.00	Kush Arvind
2024-10-23	Buy	1460000.00	Bellini Roberto
2024-07-18	Sale	-30000.00	Freeman Roy Lester
2024-07-18	Sale	-30000.00	BERMAN DENNIS N
2024-07-18	Sale	-30000.00	Dion Gisele
2024-07-18	Sale	-30000.00	GRINT PAUL C
2024-04-03	Sale	-45000.00	Werner Milton H.
2024-04-02	Sale	-90000.00	Lees-Rolfe Garth